AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada

RegulatoryAMO-02Positive

AI Analysis

Summary

AMO Pharma announced regulatory feedback from FDA, MHRA, and Health Canada regarding its planned registrational study for AMO-02 in Congenital Myotonic Dystrophy Type 1, with hospitalization as the primary outcome measure.

Clinical Trial Data

Phase

registrational

Outcome Details

Scientific advice received from FDA, MHRA, and Health Canada; registrational study planned with hospitalization as primary outcome

Importance:5/10

Sentiment:

0.30

regulatory guidancerare diseaseclinical trial designmulti-regulatory feedback

Related Companies

$HR $MEHA $HIT

Read the original article

Published by PR Newswire Biotech on July 6, 2026 9:30 PM

Read Original